Patents by Inventor Jerzy Szczepan Pieczykolan
Jerzy Szczepan Pieczykolan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9175059Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an anti-angiogenic effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.Type: GrantFiled: January 5, 2012Date of Patent: November 3, 2015Assignee: Adamed Sp. z o.o.Inventors: Jerzy Szczepan Pieczykolan, Sebastian Dominik Pawlak, Bartlomiej Maciej Żerek, Piotr Kamil Rózga
-
Patent number: 9161991Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.Type: GrantFiled: December 5, 2011Date of Patent: October 20, 2015Assignee: ADAMED sp. z o. o.Inventors: Jerzy Szczepan Pieczykolan, Krzysztof Kazimierz Lemke, Sebastian Pawlak, Bartłomiej Żerek
-
Patent number: 9102759Abstract: The fusion protein, especially recombinant, comprising domain (a) which is a functional fragment of soluble hTRAIL protein sequence beginning with an amino acid at a position not lower than hTRAIL95 or a sequence having at least 70% homology thereto; and domain (b) which is a sequence of pro-apoptotic effector peptide, wherein the sequence of domain (b) is attached at C-terminus and/or N-terminus of domain (a). The fusion protein has anticancer activity. The nucleotide sequence coding the fusion protein, expression vector and host cell for the preparation of the fusion protein, and the use of the fusion protein for treating cancer diseases.Type: GrantFiled: June 24, 2011Date of Patent: August 11, 2015Assignee: ADAMED SP. Z O.O.Inventors: Jerzy Szczepan Pieczykolan, Sebastian Pawlak, Bartlomiej Zerek, Krzysztof Kazimierz Lemke
-
Publication number: 20150044162Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino acid hTRAIL281; and domain (b) which is a sequence of an effector peptide inhibiting protein synthesis, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.Type: ApplicationFiled: November 28, 2012Publication date: February 12, 2015Inventors: Jerzy Szczepan Pieczykolan, Sebastian Pawlak, Michal Szymanik, Anna Maria Pieczykolan, Bartlomiej Maciej Zerek, Piotr Rózga, Albert Robert Jaworski, Malgorzata Izabela Teska-Kaminska
-
Publication number: 20140377216Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino acid hTRAIL281; and at least one domain (b) which is a sequence of a cytolytic effector peptide forming pores in the cell membrane, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.Type: ApplicationFiled: December 22, 2012Publication date: December 25, 2014Inventors: Jerzy Szczepan Pieczykolan, Sebastian Dominik Pawlak, Bartlomiej Maciej Zerek, Piotr Kamil Rozga
-
Publication number: 20140031283Abstract: A fusion protein comprising domain (a) which is the functional fragment of a hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and at least one domain (b) which is the sequence of an effector peptide having anti-proliferative activity against tumour cells, wherein the sequence of domain (b) is attached at the C-terminus or at the N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.Type: ApplicationFiled: April 19, 2012Publication date: January 30, 2014Applicant: ADAMED SP. Z O.O.Inventors: Jerzy Szczepan Pieczykolan, Sebastian Dominik Pawlak, Barttomie Maciej Aerek, Piotr Kamil Rózga, Urszula Marta Szawlowska
-
Publication number: 20130288963Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an anti-angiogenic effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.Type: ApplicationFiled: January 5, 2012Publication date: October 31, 2013Applicant: ADAMED SP. Z O.O.Inventors: Jerzy Szczepan Pieczykolan, Sebastian Dominik Pawlak, Bartlomiej Maciej Zerek, Piotr Kamil Rózga
-
Publication number: 20130251676Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.Type: ApplicationFiled: December 5, 2011Publication date: September 26, 2013Applicant: ADAMED SP. Z O.O.Inventors: Jerzy Szczepan Pieczykolan, Krzysztof Kazimierz Lemke, Sebastian Pawlak, Bartlomiej Zerek
-
Publication number: 20130164254Abstract: The fusion protein, especially recombinant, comprising domain (a) which is a functional fragment of soluble hTRAIL protein sequence beginning with an amino acid at a position not lower than hTRAIL95 or a sequence having at least 70% homology thereto; and domain (b) which is a sequence of pro-apoptotic effector peptide, wherein the sequence of domain (b) is attached at C-terminus and/or N-terminus of domain (a). The fusion protein has anticancer activity. The nucleotide sequence coding the fusion protein, expression vector and host cell for the preparation of the fusion protein, and the use of the fusion protein for treating cancer diseases.Type: ApplicationFiled: June 24, 2011Publication date: June 27, 2013Applicant: ADAMED SP. Z O.O.Inventors: Jerzy Szczepan Pieczykolan, Sebastian Pawlak, Bartlomiej Zerek, Krzysztof Kazimierz Lemke